Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

V 306

Next Previous
X
Search
Drug Profile

V 306

Alternative Names: Respiratory syncytial virus vaccine - Virometix; V-306

Latest Information Update: 28 Apr 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Virometix
  • Class Respiratory syncytial virus vaccines; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Respiratory syncytial virus infections

Highest Development Phases

  • No development reported Respiratory syncytial virus infections

Most Recent Events

  • 28 Apr 2023 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In volunteers) in Belgium (IM, Injection)
  • 02 Mar 2022 Virometix completes phase I trial in Respiratory syncytial virus infections (In volunteers) in Belgium (IM, Injection) (NCT04519073)
  • 14 Jul 2021 Pharmacodynamics data from a preclinical trial in Respiratory syncytial virus infection released by Virometix

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top